Tibolon: Effect in Hormone Therapy
Tibolon (brand name Liviella) is a synthetic steroid with mixed estrogenic, progestagenic, and androgenic effects. It belongs to the drug class of Selective Tissue Estrogenic Activity Regulators (STEAR) and is used for hormone therapy in postmenopausal symptoms. Tibolon was developed by Organon and has been available in Germany since the 1990s as an alternative to classical estrogen progestin therapy. The substance is taken orally once daily as a single tablet and has the advantage that no estrogen progestin sequence or combination regimen is necessary.
Tibolon has found a place in the treatment of climacteric syndrome because its individual effects are expressed differently in different tissues. In bone tissue and the brain, the estrogenic effect predominates, reducing vasomotor symptoms and providing protection against osteoporosis. In the endometrium, metabolites primarily exert a progestagenic effect, reducing the risk of endometrial hyperplasia. However, the LIFT study (Long Term Intervention on Fractures with Tibolone) and subsequent investigations have raised safety concerns regarding breast cancer risk and stroke risk in older women, which is why the indication is now more strictly defined.
Mechanism of Action
Tibolon is a prodrug that is converted into three pharmacologically active metabolites after oral administration: 3 alpha hydroxytibolon, 3 beta hydroxytibolon, and Delta 4 tibolon. The first two metabolites have predominantly estrogenic effects at estrogen receptors, while Delta 4 tibolon exerts progestagenic and androgenic activity. These metabolites have different tissue specificity: in bone, brain, and vagina, the estrogenic effect dominates, while in the endometrium, the progestagenic effect predominates.
Tissue specificity arises from different local enzyme activities. In the endometrium, tibolon is predominantly converted to Delta 4 tibolon, which minimizes the estrogenic effect on the endometrium and prevents endometrial hyperplasia. This characteristic makes tibolon a single tablet therapy without the need for a separate progestin component, which can improve compliance.
Pharmacokinetically, tibolon is rapidly absorbed after oral administration. The elimination half-life of the main metabolites is 5 to 8 hours, so once daily administration is sufficient. Metabolism occurs primarily hepatically and through sulfation. Excretion takes place primarily via bile and to a lesser extent renally.
Therapeutic Uses
- Treatment of climacteric symptoms such as hot flushes, night sweats, sleep disturbances, mood swings, vaginal dryness in postmenopausal women
- Prevention of postmenopausal osteoporosis in women with increased fracture risk when other therapy options are contraindicated or not tolerated
- Hormone therapy after hysterectomy as an alternative to estrogen monotherapy
- Adjuvant in breast cancer history: not recommended due to increased recurrence risk
Treatment should not begin until at least 12 months after the last menstruation to avoid irregular bleeding and questions regarding endometrial monitoring. In women with persistent cyclic bleeding, classical hormone therapy is initiated first.
Dosage and Administration
Adult postmenopausal women: 2.5 mg tibolon once daily orally.
Start of therapy: not before 12 months after the last menstruation.
Duration of therapy: annual reevaluation of the benefit-risk ratio, generally no longer than necessary.
Administration: take with water, preferably at the same time each day. May be taken with or without food.
Missed tablet: if less than 12 hours have passed, take immediately. Otherwise return to normal dosing schedule.
Renal impairment: generally no special adjustment necessary for moderate impairment. Individual assessment for severe impairment.
Hepatic impairment: contraindicated in severe impairment because metabolism occurs via the liver.
Important: Tibolon is not a contraceptive. In women in early postmenopause, contraceptive protection is still required if menopause is not definitively established.
Adverse Effects
Very common: Abdominal pain, weight gain, breast tenderness, postmenopausal bleeding or spotting (especially in the first months of therapy).
Common: Vaginal yeast infections, vaginal discharge, endometrial thickening, acne, hirsutism (due to androgenic component), headache, dizziness, peripheral edema, depression, pruritus.
Uncommon: Muscle and joint pain, allergic skin reactions.
Rare to very rare: Breast cancer (increased risk with long-term use, particularly in women over 60 years), endometrial cancer (increased in some studies), ovarian cancer, stroke (especially in older women), deep vein thrombosis, pulmonary embolism, cholecystitis, hepatotoxicity.
LIFT study: in women over 60 years, an increased stroke risk was observed with tibolon, which is why the indication must be carefully considered in this age group.
With premenopausal use or in women whose menopause is not established, tibolon can cause irregular bleeding.
Drug Interactions
- CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, phenobarbital, St. John's wort): reduced efficacy of tibolon, higher dose may be required.
- Anticoagulants such as warfarin, DOAC: tibolon may enhance or reduce anticoagulant effect, INR monitoring with coumarins.
- Thyroid hormones: adjustment may be necessary with substitution therapy due to changes in binding proteins.
- Other hormone preparations: combination with additional estrogens or progestins not recommended.
- Antiepileptic drugs: possible influence on plasma levels of tibolon and antiepileptic drugs.
Special Information
Pregnancy and breastfeeding: contraindicated.
Contraindications: Pregnancy and breastfeeding, known or suspected breast cancer or breast cancer history, estrogen-dependent tumors, unexplained vaginal bleeding, untreated endometrial hyperplasia, previous or current venous thromboembolism, acute or recent arterial thromboembolic events (angina pectoris, myocardial infarction, stroke), active liver disease or liver tumors, acute porphyria, known hypersensitivity to tibolon.
Before therapy: thorough gynecological examination with mammography, endometrial ultrasound, general history (thrombosis risk, cardiovascular disease, family history of hormone-dependent tumors), blood pressure, coagulation, liver and kidney values, vitamin D and bone status if indicated.
During therapy: annual gynecological check with mammography, endometrial ultrasound, blood pressure, reevaluation of indication and risks. Immediate diagnostic evaluation for unclear bleeding.
Risk profile to consider: Women over 60 years, smokers, patients with pre-existing hypertension, obesity, or diabetes have an increased risk profile for cardiovascular and thromboembolic complications.
Lifestyle: balanced diet, adequate physical activity, avoidance of nicotine, alcohol in moderation, vitamin D and calcium supplementation for osteoporosis risk.
Driving ability: generally not impaired, exercise caution if dizziness or headache occurs.
You may also be interested in
- Estradiol, classical estrogen in hormone therapy
- Dydrogesteron, progestin for endometrial protection
- Raloxifen, SERM in postmenopausal osteoporosis
- Alendronic acid, bisphosphonate in osteoporosis
- Denosumab, monoclonal antibody in osteoporosis
Frequently Asked Questions
What distinguishes tibolon from classical hormone replacement therapy?
Classical hormone replacement therapies consist of an estrogen, often combined with a progestin to protect the endometrium. Tibolon combines estrogenic, progestagenic, and androgenic effects in one molecule and does not require a separate progestin component. Furthermore, the effect differs in a tissue-specific manner, with a progestagenic component dominating in the endometrium, which is intended to reduce hyperplasia risk. However, the safety profile regarding breast cancer and stroke is not more favorable than with classical hormone replacement therapy in some studies.
For which women is tibolon suitable?
Tibolon is an option for postmenopausal women with pronounced climacteric symptoms or increased osteoporosis risk when classical hormone replacement therapy is not tolerated or causes unwanted bleeding. Tibolon is not suitable in women with breast cancer history, high thrombosis risk, stroke risk, or in women over 60 years without a strict indication.
How long may tibolon be taken?
There is no fixed maximum duration, but therapy should be as short as possible and as long as necessary. At least annual gynecological reevaluation of indication and benefit-risk ratio is mandatory. Studies show an increase in breast cancer risk after 5 years of use, so longer therapy is only justified with clear indication and risk profile.
What to do for vaginal bleeding on tibolon?
In the first months of therapy, spotting or minor bleeding may occur, which usually resolves on its own. However, persistent, heavy, or late-onset bleeding must always be medically evaluated because it may indicate endometrial pathology. Usually transvaginal ultrasound and, if necessary, endometrial biopsy are performed for clarification.
Sources
- Gelbe Liste, Tibolon Active Ingredient Profile
- BfArM, Federal Institute for Drugs and Medical Devices
- German Society for Gynecology and Obstetrics (DGGG)
- AWMF S3 Guideline Hormone Therapy in Peri and Postmenopause
- European Medicines Agency, EPAR Liviella
Legal Information and Liability Disclaimer
The information provided on this page is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendation. It does not replace the advice of an approved physician or pharmacist. Tibolon is a prescription-only medicine and should be used exclusively under gynecological supervision with individual benefit-risk assessment. All information is based on published package inserts and recognized scientific sources at the time of publication, with the current manufacturer's package insert being authoritative. Sanoliste assumes no liability for completeness, timeliness, or accuracy of the information presented. In the event of a medical emergency, call the emergency number 112.